The slumber continues...Interview with Dr. William Carter, CEO of Hemispherx Biopharma
"An interview with Dr. William Carter, CEO of Hemispherx Biopharma (AMEX:HEB) regarding the status of the NDA for Ampligen as a first line treatment for Chronic Fatigue Syndrome as well as his company's pipeline plans for Alferon LDO (Low Dose Oral) application." - That's nice but all I want to know now is if Ampligen is going to be approved or not by the FDA. WTF is going on?
"An interview with Dr. William Carter, CEO of Hemispherx Biopharma (AMEX:HEB) regarding the status of the NDA for Ampligen as a first line treatment for Chronic Fatigue Syndrome as well as his company's pipeline plans for Alferon LDO (Low Dose Oral) application." - That's nice but all I want to know now is if Ampligen is going to be approved or not by the FDA. WTF is going on?
No comments:
Post a Comment